133 related articles for article (PubMed ID: 27440209)
1. Highlights from the 2016 Schizophrenia International Research Society Conference, April 2-6, 2016.
Solis M
Clin Schizophr Relat Psychoses; 2016; 10(2):89-92. PubMed ID: 27440209
[TBL] [Abstract][Full Text] [Related]
2. Highlights from the 2014 Schizophrenia International Research Society Conference April 5-9, 2014.
Curley AA
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):81-3. PubMed ID: 25061011
[TBL] [Abstract][Full Text] [Related]
3. Highlights from the 2012 Schizophrenia International Research Society Conference, April 14-18, 2012.
Heimer H; Solis M
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):55-60. PubMed ID: 22776631
[TBL] [Abstract][Full Text] [Related]
4. Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), March 24-March 28, 2017.
Heimer H
Clin Schizophr Relat Psychoses; 2017; 11(2):91-94. PubMed ID: 28742395
[TBL] [Abstract][Full Text] [Related]
5. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.
Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA
J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119
[TBL] [Abstract][Full Text] [Related]
6. Highlights from the new drug session at the Biennial International Congress On Schizophrenia Research, April 2-6, 2011.
Heimer H
Clin Schizophr Relat Psychoses; 2011 Jul; 5(2):72-4. PubMed ID: 21693429
[TBL] [Abstract][Full Text] [Related]
7. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.
Mu Q; Johnson K; Morgan PS; Grenesko EL; Molnar CE; Anderson B; Nahas Z; Kozel FA; Kose S; Knable M; Fernandes P; Nichols DE; Mailman RB; George MS
Schizophr Res; 2007 Aug; 94(1-3):332-41. PubMed ID: 17596915
[TBL] [Abstract][Full Text] [Related]
8. Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
Luquin MR; Guillén J; Legarda I; Cruz Rodriguez M; Del Rio L; Dominguez J; Martínez-Lage JM
Adv Neurol; 1996; 69():239-44. PubMed ID: 8615134
[No Abstract] [Full Text] [Related]
9. Partial agonism and schizophrenia.
Bolonna AA; Kerwin RW
Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
[No Abstract] [Full Text] [Related]
10. Schizophrenia research: a biennium of progress. Proceedings from the Sixth International Congress on Schizophrenia Research. Colorado Springs, CO, April 12-16, 1997.
Buchanan RW; Buckley PF; Tamminga CA; Schulz SC
Schizophr Bull; 1998; 24(4):501-18. PubMed ID: 9853785
[TBL] [Abstract][Full Text] [Related]
11. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.
George MS; Molnar CE; Grenesko EL; Anderson B; Mu Q; Johnson K; Nahas Z; Knable M; Fernandes P; Juncos J; Huang X; Nichols DE; Mailman RB
Schizophr Res; 2007 Jul; 93(1-3):42-50. PubMed ID: 17467956
[TBL] [Abstract][Full Text] [Related]
12. Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), April 21-25, 2013.
Curley AA; Fisher HL
Clin Schizophr Relat Psychoses; 2013; 7(2):68-72. PubMed ID: 23841955
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
14. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of dopamine D1 and D2 receptor agonists on schedule-controlled behavior of squirrel monkeys.
Bergman J; Rosenzweig-Lipson S; Spealman RD
J Pharmacol Exp Ther; 1995 Apr; 273(1):40-8. PubMed ID: 7714795
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.
Terzić T; Kastelic M; Dolžan V; Plesničar BK
Psychiatr Danub; 2016 Jun; 28(2):127-31. PubMed ID: 27287786
[TBL] [Abstract][Full Text] [Related]
17. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery.
Carlsson A; Carlsson ML
Dialogues Clin Neurosci; 2006; 8(1):137-42. PubMed ID: 16640125
[TBL] [Abstract][Full Text] [Related]
18. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review.
Schacht JP
Pharmacogenomics J; 2016 Oct; 16(5):430-8. PubMed ID: 27241058
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice.
Ralph-Williams RJ; Lehmann-Masten V; Geyer MA
Neuropsychopharmacology; 2003 Jan; 28(1):108-18. PubMed ID: 12496946
[TBL] [Abstract][Full Text] [Related]
20. The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.
Takase M; Kanahara N; Oda Y; Niitsu T; Watanabe H; Iyo M
Schizophr Res; 2017 Dec; 190():182-183. PubMed ID: 28285026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
